Lutethium-177 (Lu-177) has become one of the most important tools in the fight against cancer. As demand grows for radioligand therapies that can target tumors with incredible precision, researchers and clinicians are looking for the top-rated suppliers of Lu-177 for cancer research. Reliable supply is critical for ensuring that patients in need have consistent access once treatments are approved.
The Role of Lu-177 in Cancer Research
Lu-177 is a beta-emitting radioisotope that delivers targeted radiation directly to cancer cells while sparing much of the surrounding healthy tissue. Because it can be attached to molecules designed to seek out specific tumor markers, it has proven especially useful in treating neuroendocrine tumors and prostate cancers. Clinical trials have expanded into other tumor types as well, making this isotope one of the most versatile tools in nuclear medicine today.
The growing interest in radioligand therapy has created a surge in demand for high-quality, dependable Lu-177 supplies. That’s why identifying the best-rated suppliers of Lu-177 for cancer research is so important. Researchers and pharmaceutical companies can’t afford delays caused by inconsistent production or limited access. With carrier-added and noncarrier-added versions available, the right supplier can make the difference between a program that stalls and one that successfully reaches patients.
Who Are the Top-Rated Suppliers of Lu-177 for Cancer Research?
Several companies have emerged as trusted leaders in the global supply of Lu-177. Each offers different strengths, from regulatory approvals and large-scale production to long-standing reactor experience and international distribution networks.
1. SHINE Technologies
SHINE Technologies makes Ilumira, a noncarrier-added (n.c.a.) version of Lu-177. Its Cassiopeia facility in Wisconsin is the largest production site of its kind in North America. It can make around 100,000 doses a year and plans to double that in the future. Because it manages the whole process itself, SHINE can offer more control over quality and timing than suppliers relying on outside partners.
Reliability is another big selling point. SHINE has reported over 95% on-time delivery, shipping Lu-177 to customers across 19 countries on four continents. With cGMP compliance and an FDA Drug Master File in place, researchers can count on their isotope meeting regulatory requirements for trials and therapies.
Key features:
N.c.a. Lu-177 — Ilumira — made under cGMP in the U.S.
High capacity of 100,000 doses per year, with plans to scale to 200,000
Fully integrated production process
Global reach with more than 95% on-time delivery
FDA Drug Master File already submitted
2. NRG PALLAS
NRG PALLAS operates the High Flux Reactor in Petten, Netherlands, one of Europe’s key isotope production sites. This facility runs multiple production cycles each year and plays a significant role in meeting global demand for Lu-177.
In 2024, NRG PALLAS signed a long-term agreement with Curium to boost Lu-177 output, particularly the noncarrier-added type. For European researchers, this is a huge step toward ensuring a stable, local supply of the isotope for trials and treatments.
Key features:
High-volume isotope production in Petten
Long-term partnership with Curium to expand supply
Major role in Europe’s Lu-177 supply chain
Focus on n.c.a. Lu-177 production
3. NTP Radioisotopes
NTP, based in South Africa, has decades of experience in isotope production and distribution. While best known for molybdenum-99, it now also produces noncarrier-added Lu-177, using the ytterbium-176 route for higher purity and efficiency.
The company recently renewed and expanded its supply agreement with ITM, reinforcing its role as a reliable partner in the global Lu-177 supply chain. NTP’s integrated infrastructure makes it particularly valuable for groups looking for consistent production and dependable distribution.
Key features:
Vertically integrated isotope production and distribution
Licensed agreement with ITM to supply n.c.a. Lu-177
Focus on high-purity production methods
Strong track record in global isotope logistics
4. Eckert & Ziegler (EZAG)
Eckert & Ziegler produces GMP-grade n.c.a. Lu-177 for research and clinical use. It’s known for supplying isotopes and for offering radiopharmaceutical services, making it a useful partner for companies needing more than just the raw isotope.
Recently, the company signed a global supply agreement with GlyTherix, showing its ability to scale and deliver for international studies. EZAG’s track record in supporting global trials makes it a dependable option for groups preparing to move from the lab into larger studies.
Key features:
GMP-compliant n.c.a. Lu-177 supply
Experience with global clinical programs
Partnerships with biotech developers
Strong regulatory and logistics support
5. University of Missouri Research Reactor (MURR)
MURR is among the oldest and most trusted isotope producers in the U.S. For years, it supplied carrier-added Lu-177, and in late 2023, it began shipping noncarrier-added Lu-177 for human use. Novartis, the maker of Lutathera, is already receiving weekly shipments from it.
MURR has also filed with the FDA to support its new process, signaling a long-term commitment to Lu-177 production. With decades of reactor experience and a track record in supplying isotopes for approved therapies, MURR is seen as a steady, reliable source.
Key features:
Long-standing U.S. isotope producer
Weekly n.c.a. Lu-177 shipments to Novartis
FDA submission for expanded production process
Experience supporting approved radiopharmaceuticals
Supplier Choice Matters
As radioligand therapies move further into mainstream oncology, dependable access to Lu-177 is more important than ever. The top-rated suppliers of Lu-177 for cancer research are making it possible for researchers to scale trials and bring life-changing treatments to patients. By choosing the right supplier, organizations can focus on advancing science while knowing their isotope needs are in safe, reliable hands.
